Last reviewed · How we verify
Empagliflozin Arm
At a glance
| Generic name | Empagliflozin Arm |
|---|---|
| Also known as | Mellitofix 10 mg |
| Sponsor | University of Alabama at Birmingham |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Antithrombotic Activities of Sotagliflozin vs. Empagliflozin (PHASE4)
- A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) (PHASE3)
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease (PHASE3)
- Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) (NA)
- The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity (PHASE4)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy (PHASE2)
- CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Empagliflozin Arm CI brief — competitive landscape report
- Empagliflozin Arm updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI